Fractyl Health, Inc.

Stage 4 · Declining · week 12

As of Oct 22, 2026, Fractyl Health is in Stage 4, the downtrend phase, now in week 12 (since Aug 5, 2026). It closed at $1.13, 96.0% below its 52-week high and below its 200-day average, which is falling.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. More about the company

$1.13

-1.74% today

$15.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GUTS early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-02-02 → 2026-10-22

S? 41w

S4 27w

S4 12w

S1 13w

2024-02-022026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S4 27w → S1 9w → S2 2w → S4 12w → S1 5w → S2 9w → S3 2w → S4 10w → S1 13w → S4 11w current

Total tracked: 142 weeks across 11 stage runs.

GUTS among Biotechnology519th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…519	GUTSFractyl Health, Inc.	Stage 4 · wk 12	6	−80.6%

vs 52W High

-96.0%

$1.13 lo$28.44 hi

96.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 12

1w13w26w

Week 12, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-86.8%

200 DMA: $8.58 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.04x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-80.6%

-87.8%

-83.8%

YTD

-95.8%

-93.0%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S4

Wk 12 · Vol 1.04x

2026-10-21S4

Wk 11 · Vol 2.11x

2026-10-20S4

Wk 11 · Vol 1.01x

2026-10-19S4

Wk 11 · Vol 2.55x

2026-10-16S4

Wk 11 · Vol 100.14x

2026-10-15S4

Wk 11 · Vol 0.66x

2026-10-14S4

Wk 10 · Vol 1.33x

2026-10-13S4

Wk 10 · Vol 1.52x

2026-10-12S4

Wk 10 · Vol 0.94x

2026-10-09S4

Wk 10 · Vol 1.41x

2026-10-08S4

Wk 10 · Vol 2.20x

2026-10-07S4

Wk 9 · Vol 0.73x

Moving averages & range

50 DMA

$6.32

200 DMA

$8.58

52W High

$28.44

52W Low

$1.13

5D Low

$1.13

Resistance levels (recent highs)

20d High

$6.53

60d High

$9.41

120d High

$11.45

250d High

$28.44

Next resistance

+477.7%

to 20d High

Dividend Yield

0.00%

P/B -9.0

Fractyl Health: quick answers

What stage is Fractyl Health in?

As of Oct 22, 2026, Fractyl Health (GUTS) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 5, 2026 and is in week 12. What the four stages mean

Is Fractyl Health in an uptrend?

No. Fractyl Health is in a Stage 4 downtrend. It trades 86.8% below its 200-day average, which is falling.

How far is Fractyl Health from its 52-week high?

Fractyl Health closed at $1.13 on Oct 22, 2026, 96.0% below its 52-week high of $28.44. Its 52-week low is $1.13.

How has Fractyl Health performed over the past year?

As of Oct 22, 2026, Fractyl Health is down 93.0% over the past year and down 95.8% so far in 2026.

Which sector and industry is Fractyl Health in?

Fractyl Health is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.